Compare Inovio Pharmaceuticals Inc (INO) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Old Dominion Freight Line Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Old Dominion Freight Line Inc trades at $183.23 (market cap $37.68B). The key difference: Old Dominion Freight Line Inc is far larger — about 335.9× Inovio Pharmaceuticals Inc's market cap, and Old Dominion Freight Line Inc pays a 0.64% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Old Dominion Freight Line Inc for 76 Days on average.
| INO | ODFL | |
|---|---|---|
Market Cap | $112.19M | $37.68B |
Volume | 3,201,278 | 1,550,104 |
Sector | Health | Industrials |
52-Week High | $2.65 | $248.73 |
52-Week Low | $0.66 | $126.29 |
Typical Hold Time | 43 Days | 76 Days |
Enterprise Value | $83.51M | $37.42B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Old Dominion Freight Line (ODFL) trades at $175.61, down 1.35% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.68 exceeding the $1.54 estimate. Revenue for 2025 was $5.50B, with a net income margin of 19.44%. A 4.9% general rate increase effective October 5, 2026, aims to support service investments amid cost pressures.
ODFL presents a mixed outlook; analyst consensus is a Buy with a $230.93 price target, implying significant upside, but technical indicators suggest near-term pressure. Risks include freight demand volatility and high valuation multiples. The stock's investment case hinges on execution of rate increases and sustained operational efficiency in a competitive trucking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
